Abstract:Radiation therapy is a commonly applied initial definitive treatment for prostate cancer. Prostate Specific Membrane Antigen (PSMA) is overexpressed in prostate cancer cells and is used as an effective diagnostic and therapeutic target. Targeting prostate cancer with anti-PSMA nanoparticles is a promising methodology, with the potential to minimize the side effects and toxicity of anticancer drugs. The objective of this study is to evaluate the radiobiological effects of PSMA-targeted gold nanoparticles (GNPs) as a theranostic tool for prostate cancer imaging and radiosensitization. The preparation of PSMA-targeted GNPs (PSMA-GNPs) was performed by covalently conjugating anti-PSMA monoclonal antibodies to 15 nm diameter GNPs. The number of GNPs that bind to PSMA positive prostate cancer cells were imaged and quantified by dark-field microscopy. The number of radiation-induced damage foci per cell were quantified by immunofluorescent staining for γ-H2AX. The ability of prostate cancer cells to grow into colonies was measured by colony formation assay. Prostate tumor xenograft models were propagated by the injection of prostate cancer cell lines orthotopically into immunodeficient mice. Mouse tumor xenografts were monitored by multimodality tumor imaging, including X-ray fluorescence (XRF), cone beam computed tomography (CBCT), and bioluminescence tomography. By dark-field microscopy, we found that PSMA-GNPs preferentially bind to PSMA positive LNCaP cells over PSMA negative PC3 cells. In PSMA positive LNCaP cells, we observed a 30% increase in DNA double strand breaks, as quantified by γ-H2AX foci number when PSMA-GNPs were added to radiotherapy (RT, single fraction 5 Gy), compared to RT plus control IgG nanoparticles. However, we did not observe that PSMA-GNPs enhanced DNA damage in PSMA negative PC3 cells. We also found a reduction in LNCaP colony formation by when PSMA-GNPs were added to RT. However, we did not observe radiosensitization in PSMA negative PC3 cells. In the tumor xenograft models, we found that PSMA-GNPs preferentially accumulate in PSMA positive LNCaP tumor xenografts by X-ray fluorescence. PSMA targeted GNPs have a highly specific binding efficiency to PSMA positive prostate cancer cells, which through X-ray fluorescence tomography may be used for the identification of tumor spatial distribution and quantification of nanoparticle binding. The addition of PSMA-GNPs to RT resulted in increased double strand breaks, cell death and inhibition of tumor growth. PSMA-GNPs are novel theranostic tools for tumor imaging and radiosensitization.

MRI of Prostate Stem Cell Antigen Expression in Prostate Tumors

Mri Of Prostate Cancer Antigen Expression For Diagnosis And Immunotherapy

MRl of Prostate Cancer Antigen Expression for Diagnosis and lmmunotherapy

Targeted Contrast Agent Specific to an Oncoprotein in Tumor Microenvironment with the Potential for Detection and Risk Stratification of Prostate Cancer with MRI.

Prostate Cancer Targeted MRI Nanoprobe Based on Superparamagnetic Iron Oxide and Copolymer of Poly(ethylene Glycol) and Polyethyleneimin

Molecular Magnetic Resonance Imaging of Tumors with a PTPµ Targeted Contrast Agent.

Enhancing Prostate-Cancer-Specific MRI by Genetic Amplified Nanoparticle Tumor Homing

A Preliminary Study of PSMA Fluorescent Probe for Targeted Fluorescence Imaging of Prostate Cancer

Molecular MR Imaging of Prostate Cancer by Specified Iron Oxide Nanoparticles With PSMA-11 Peptides: A Preclinical Study

A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen

Real-time precision targeted prostate biopsy using transrectal ultrasound-magnetic resonance fusion

Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA

Evaluation of PSMA-Targeted Theranostic Gold Nanoparticles for Prostate Cancer Imaging and Radiosensitization

Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer

The imaging study of a small-molecular inhibitor targeting prostate speciifc membrane antigen

Preclinical Evaluation of a Fibroblast Activation Protein and a Prostate-Specific Membrane Antigen Dual-Targeted Probe for Noninvasive Prostate Cancer Imaging

Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer

Development and Characterization of an Antibody-Labeled Super-Paramagnetic Iron Oxide Contrast Agent Targeting Prostate Cancer Cells for Magnetic Resonance Imaging

Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen

Preliminary Clinical Study of (99M)tc-Labelled Small Molecules Against PSMA for Prostate Cancer Imaging

PDGF-B conjugating mesoporous IO/GdO nanocomposites for accurate diagnosis of orthotopic prostatic cancer through T1-T2 dual-modal MRI contrast enhancement